← Leaderboards
Zachary N Warnken
Via Therapeutics, Llc
$1,027,895
Attributed
$1,185,076
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $628.7K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,185,076 · 4
By mechanism
R41$928,726 · 3
R43$256,350 · 1
Top collaborators
- Zhengrong Cui1 shared
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseMouse ModelPropertyLungRegimenThinnessTuberculosisDrug KineticsPowder Dose FormMacrophagePrototypePublic HealthSuspensionsTechnologyFreeze DryingLifeDrynessInhalationAerosolsDisabilityFilmMissionAntibioticsUnited States National Institutes Of Health
Grant awards (4)
Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatment of NTM$314,363
R41 · FY2025 · AI · contact PI
Microneedle-based mRNA Flu Vaccine for Transcutaneous Immunization$314,363
R41 · FY2025 · AI · contact PI
Inhalable dry powders of mycobacteriophages for tuberculosis therapy$300,000
R41 · FY2024 · AI · contact PI
Development of synergistic clofazimine-amikacin inhalable powders for the treatment of pulmonary Mycobacterium abscessus infections$256,350
R43 · FY2021 · AI · contact PI